Search

Author/Creator Peter, Nuala

1. Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext). (3rd October 2019)

Authors:
Cohen, Stanley B.; Czeloth, Niklas; Lee, Eric; Klimiuk, Piotr A.; Peter, Nuala; Jayadeva, Girish
Journal:
Expert opinion on biological therapy
Issue:
Volume 19:Number 10(2019)
Page Start:
1097
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Issue 6 (7th March 2018)

Authors:
Cohen, Stanley B; Alonso-Ruiz, Alberto; Klimiuk, Piotr A; Lee, Eric C; Peter, Nuala; Sonderegger, Ivo; Assudani, Deepak
Journal:
Annals of the rheumatic diseases
Issue:
Volume 77:Issue 6(2018)
Page Start:
914
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗